title: Impulse control disorders in Parkinson's disease in a Chinese population.
abstract: BACKGROUND
  Dopamine agonists have been used as first-line treatments for patients with Parkinson's disease (PD) during its early stage, and several impulse control disorder (ICD) behaviors have been reported to be associated with their use.
  
  
  OBJECTIVE
  To investigate the association between ICD behaviors and the use of agonists in Chinese patients with PD and associated risk factors.
  
  
  METHODS
  Self-report screening questionnaires were mailed to 400 PD patients treated with anti-parkinsonian drugs in our clinical database and their spouses (served as control group). Those who screened positive for ICD behaviors by questionnaire were further interviewed over the telephone by a movement disorder specialist to confirm the diagnosis.
  
  
  RESULTS
  A total of 11 (3.53%) patients were diagnosed with ICD behaviors as follows: lifetime pathological gambling (1, 0.32%); subclinical or clinical hypersexuality (6, 1.92%); binge eating (1, 0.32%); dopamine dysregulation syndrome (2, 0.64%); and compulsive internet browsing (1, 0.32%). ICD behaviors were associated with an increased mean levodopa equivalent daily dosage and alcohol use (p=0.005 and p=0.002, respectively). Patients using dopamine agonists were significantly (p=0.003) more likely to be diagnosed with an ICD (6.3%) as compared to those who were not (0.6%).
  
  
  CONCLUSIONS
  PD patients who took dopamine agonists were more likely to report ICD behaviors in Chinese PD.
authors: Department of Neurology and Neurobiology, Key Laboratory of Neurodegenerative Disease of Ministry of Education, Beijing Institution of Geriatrics and Xuanwu Hospital of Capital Medical University, China.
authors: WenHui
authors: W
authors: Fan
authors: Hui
authors: H
authors: Ding
authors: JingHong
authors: J
authors: Ma
authors: Piu
authors: P
authors: Chan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000428:Alcohol Drinking / Q000453:epidemiology; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000494:pharmacology; D002681:China / Q000453:epidemiology; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000139:chemically induced / Q000453:epidemiology*; D018491:Dopamine Agonists / Q000009:adverse effects / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007407:Interviews as Topic; D007980:Levodopa / Q000009:adverse effects / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000453:epidemiology*; D011795:Surveys and Questionnaires
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007980:Levodopa